The estimated Net Worth of Allen Yang is at least $4.88 Milhão dollars as of 9 March 2023. Allen Yang owns over 1,094 units of Xencor Inc stock worth over $1,550,181 and over the last 5 years he sold XNCR stock worth over $595,961. In addition, he makes $2,732,090 as Senior Vice President e Chief Medical Officer at Xencor Inc.
Sign up
Allen Yang XNCR stock SEC Form 4 insiders trading
Allen has made over 6 trades of the Xencor Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,094 units of XNCR stock worth $32,689 on 9 March 2023.
The largest trade he's ever made was selling 4,069 units of Xencor Inc stock on 6 March 2023 worth over $127,848. On average, Allen trades about 1,754 units every 81 days since 2019. As of 9 March 2023 he still owns at least 73,364 units of Xencor Inc stock.
You can see the complete history of Allen Yang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Allen Yang biography
Dr. Allen Yang M.D., Ph.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Yang has served our Senior Vice President and Chief Medical Officer since December 2019. Dr. Yang oversees all aspects of clinical development for the Company, including clinical development, clinical operations, biometrics, pharmacovigilance, and medical writing. From January 2019 to December 2019, he served as senior vice president, head of clinical development and acting chief medical officer at Jazz Pharmaceuticals. Prior to joining Jazz in April 2016, Dr. Yang led clinical development and clinical operations groups at Spectrum Pharmaceuticals, where he was vice president of clinical research from 2014 to March 2016. From 2009 to 2014, he held several roles of increasing responsibility at Amgen, including those of global development leader for an oncology therapeutic and clinical research medical director for the first approved bispecific antibody. Before transitioning to the biopharmaceutical industry, from 2004 to 2009, Dr. Yang practiced medicine as an academic oncologist at the University of Southern California, where he led a translational cancer research laboratory. Dr. Yang received a B.A. in molecular biology from the University of California, Berkeley, and a Ph.D. in biochemistry and an M.D. from the University of Southern California. He completed his medical oncology fellowship at the MD Anderson Cancer Center.
What is the salary of Allen Yang?
As the Senior Vice President e Chief Medical Officer of Xencor Inc, the total compensation of Allen Yang at Xencor Inc is $2,732,090. There are 1 executives at Xencor Inc getting paid more, with Bassil Dahiyat having the highest compensation of $3,731,510.
How old is Allen Yang?
Allen Yang is 52, he's been the Senior Vice President e Chief Medical Officer of Xencor Inc since 2019. There are 11 older and 6 younger executives at Xencor Inc. The oldest executive at Xencor Inc is Richard Ranieri, 67, who is the Independent Director.
What's Allen Yang's mailing address?
Allen's mailing address filed with the SEC is , C/O XENCOR, INC., MONROVIA, CA, 91016.
Insiders trading at Xencor Inc
Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford, eJohn S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.
What does Xencor Inc do?
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
What does Xencor Inc's logo look like?
Complete history of Allen Yang stock trades at Xencor Inc
Xencor Inc executives and stock owners
Xencor Inc executives and other stock owners filed with the SEC include:
-
Bassil Dahiyat,
President, Chief Executive Officer, Founder and Director -
Allen Yang,
Senior Vice President, Chief Medical Officer -
Celia Eckert,
Vice President, General Counsel, Corporate Secretary -
John Desjarlais,
Senior Vice President, Research and Chief Scientific Officer -
John Kuch,
Chief Financial Officer, Vice President -
Dr. Bassil I. Dahiyat Ph.D.,
Co-Founder, CEO, Pres & Director -
Dr. Allen S. Yang M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Dr. John R. Desjarlais,
Sr. VP of Research & Chief Scientific Officer -
Celia E. Eckert J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
John J. Kuch,
Sr. VP & CFO -
A. Bruce Montgomery,
Lead Independent Director -
Dagmar Rosa-Bjorkeson,
Independent Director -
Kurt Gustafson,
Independent Director -
Yujiro Hata,
Independent Director -
Richard Ranieri,
Independent Director -
Kevin Gorman,
Independent Director -
Ellen Feigal,
Independent Director -
Julie Casciani,
Executive Director - Human Resources -
Kirk Rosemark,
Vice President, Regulatory Affairs and Quality Assurance -
Eric Kowack,
Vice President, Program Leadership and Strategic Alliances -
Jeremy Grunstein,
Vice President of Business Development -
Kirk Rosemark RAC,
Sr. VP of Regulatory Affairs & Quality Assurance -
Jennifer Sandoz,
VP of HR -
Charles Liles,
Associate Director and Head of Corp. Communications & Investor Relations -
John S Iii Ronin Capital, L...,
-
Paul A Foster,
Chief Medical Officer -
Barbara Klencke,
Director -
Bruce L A Carter,
Director -
Edgardo Jr Baracchini,
Chief Business Officer -
Robert Jr. Baltera,
Director -
Bart Jan Cornelissen,
SR. VICE PRESIDENT & CFO -
John S Jr Stafford,
10% owner -
Trading, Llc Ronin,
10% owner -
Lloyd A Rowland,
Sr. V.P. and General Counsel -
Atul Saran,
Director -
Harold R Werner,
Director -
Jonathan Fleming,
Director -
John S Iii Stafford,
10% owner -
Capital, Llcstafford John S...,
-
Nancy Valente,
EVP, Chief Development Officer